0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Cell > TL1A > SCRAJ-STT204

Raji/Membrane-Bound Human TL1A Stable Cell Line Development Service

Order Now

This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Description
    Raji/Membrane-Bound Human TL1A Stable Cell Line Development Service
  • Application

    • Useful for cell-based TL1A binding assay

  • Growth Properties
    Suspension
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    RPMI-1640 + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
  • Background
    TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.
  • Permits & Restrictions
    This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)

Price(EUR) : €3540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:4 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken